Poultry and Livestock Vaccines Strategic Analysis & Growth Outlook 2033

Poultry and Livestock Vaccines by Application (Chicken, Pig, Others), by Type (Live Vaccine, Inactivated vaccine), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 134

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 134

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Poultry and Livestock Vaccines Market Size | CAGR 18.5 Forecast 2033

Poultry and Livestock Vaccines Strategic Analysis & Growth Outlook 2033

🏭 Healthcare🌍 Global

Pages: 134

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 134

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Poultry and Livestock Vaccines Market Overview

The global Poultry and Livestock Vaccines market—prophylactic biologicals that protect broilers, layers, swine, cattle, aquaculture and companion animals from viral, bacterial and parasitic diseases—plays a pivotal role in safeguarding the global protein supply chain and One Health security. Driven by an expanding market size that is forecast to reach USD 11.2 billion by 2033, the sector’s growth outlook is underpinned by a resilient 7.4% CAGR (2026-2033) as producers scale vaccination to offset AGP (antibiotic growth promoter) withdrawals and heightened export health standards.

Loading chart…

Macro drivers of industry expansion include intensifying zoonotic disease pressure (H5N1, ASF, PEDv), regulatory mandates for farm-level traceability, and consumer-driven shifts toward antibiotic-free protein. The competitive landscape is being reshaped by mRNA and DIVA-compatible vector platforms, strategic M&A among tier-one animal-health giants, and regionalised fill-finish hubs to shorten cold-chain lead times. North America currently commands the largest market share, while Asia-Pacific is the fastest-growing region, fuelled by mega-integrated pork and poultry complexes, rising veterinary health expenditure and government-led compulsory vaccination schemes.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Boehringer Ingelheim; Ceva; Zoetis; Vaxxinova®; Elanco; QYH Biotech Co., Ltd; Pulike; Phibro Animal Health Corporation; JinYu Biotechnology; Harbin Pharmaceutical Group; MEVAC; Venky's; Japfa Comfeed Indonesia; Nisseiken; Hile; Hester Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Intensifying global protein demand—especially in Asia-Pacific and LATAM—pushes integrators toward high-density production systems where vaccination is a biosecurity license to operate, directly expanding the Poultry and Livestock Vaccines market size at a CAGR of 7–8% through 2030.

Regulatory momentum (US VFD, EU Farm-to-Fork, India’s 2022 AMR standards) is accelerating the exit from prophylactic antibiotics; vaccines are the only cost-effective, residue-free alternative, driving >60% of new product R&D pipelines.

Restraints

Cold-chain gaps in lower-middle-income countries inflate total delivered cost by 18–22%, deterring uptake of high-margin mRNA and vectorized vaccines and compressing gross-to-net margins for multinational suppliers.

Vaccine failure under antigenic drift (e.g., variant IBV QX, PRRS-2) erodes producer trust, elongating customer conversion cycles and increasing post-outbreak compensation claims that shave 2–3 pp off segment EBIT.

Opportunities

Rapid divalent and trivalent intranasal platforms paired with in ovo delivery devices cut labor 40% and open premium pricing (+25% vs. injectables), creating a $1.4 bn whitespace in 7-day-old broiler programs.

Data-driven vaccine-plus-analytics bundles (sensor + SaaS + autogenous vaccine) lock in five-year contracts, lifting customer lifetime value 3× and insulating suppliers from generic aqueous formulations.

Challenges

Regulatory harmonization bottlenecks (OIE vs. country-specific dossiers) stretch launch timelines to 5–7 years, forcing early-stage partnerships that dilute IP ownership and raise break-even thresholds.

Intensifying grain and energy inflation squeezes producer cash margins, prompting immediate cost rationalization that prioritizes feed over preventive health, a headwind to growth forecast realization in 2024–25.

Market Segmentation

Loading chart…

Application segmentation in the Poultry Vaccines market reflects the epidemiological risk profile of each production stage. Broiler vaccines dominate value share because birds reach slaughter weight in <40 days; any infection translates into immediate carcass downgrade and lost feed conversion, so in ovo and day-old spray cabinet programs are universal. Breeder vaccinations command higher unit prices due to longer immunity requirements (≥60 weeks) and the need to block vertical transmission of pathogens such as Mycoplasma synoviae; combined live + killed protocols drive per-dose revenue 4–5× above broiler levels. Layer applications are increasingly split: early life programs mirror breeders, while in-vivo mRNA titers against variant H9N2 or IBV QX are emerging as premium SKUs. Overall, the Poultry and Livestock Vaccines segmentation shows that broiler volumes secure scale, whereas breeder and late-layer SKUs secure margin.

Type segmentation differentiates technology platforms by immunological onset speed and duration of immunity (DOI). Live attenuated vaccines still represent the largest value slice; they provide rapid, solid immunity for mass administration via spray or drinking water, keeping cost per bird below USD 0.03. Inactivated (killed) vaccines, usually oil-emulsified, generate high-titer IgG antibodies; although 6–8× costlier, they are critical for long-lived breeders and layers and are delivered in conjunction with live priming. Recombinant vector platforms—notably HVT-IBD or HVT-NDV constructs—are the fastest-growing subsegment (+11 % CAGR) because they fit into DIVA strategies and avoid maternally derived antibody interference. Finally, DNA/mRNA candidates, still <2 % of 2023 poultry revenue, are attracting venture funding for their thermostability and ability to target multiple serotypes without cold-chain burden, positioning them as the next inflection point in market taxonomy.

Application segmentation in the Livestock Vaccines market is governed by herd replacement cycles and biosecurity economics. Cattle generate the largest share of demand; dairy replacements require repeated immunization against BVD, IBR, Leptospira, and Pasteurella, creating annual booster revenue, while feedlot calves contribute through one-shot combination doses at feedlot entry. Swine follows, with sow-herd vaccination against PRRS, Porcine Circovirus-2, and Mycoplasma hyopneumoniae locking in predictable quarterly sales; growing 2-site and 3-site production systems increase wean-to-finish vaccination compliance. Sheep & goat applications remain fragmented but are expanding for Clostridial 7-way and Toxoplasma vaccines as export markets impose residue-free certification. Within Poultry and Livestock Vaccines segmentation, cattle commands a 55 % value share, swine 28 %, and small ruminants 8 %; aquaculture, though nascent, is accelerating at 14 % CAGR off a low base.

Type segmentation reveals a technology shift toward subunit and mRNA formats that satisfy DIVA-compatible export protocols. Inactivated vaccines still dominate value because they deliver 12-month DOI with aluminum-hydroxide or oil-emulsion adjuvants, critical for extensive cattle operations. Live attenuated bacterial vaccines (e.g., RB51 for brucellosis) are restricted to government-monitored zones yet remain pivotal for zoonosis control. Toxoid formulations against Clostridial diseases represent a high-volume, low-price commodity cluster with slim margins. Recombinant subunit antigens—such as E. coli expressing PCV-2 capsid protein—are growing 9 % annually as they eliminate post-vaccination shedding, aligning with antibiotic-free certification. Finally, DNA and mRNA vaccines for livestock are entering initial field trials for ASFV and FMDV, but regulatory pathways for vaccine banks and platform licensure will determine whether they reshape market taxonomy beyond the current <1 % revenue share.

Poultry and Livestock Vaccines Segmentation Breakdown7 items

Application

Chicken

Pig

Others

Type

Live Vaccine

Inactivated vaccine

Regional Insights

Loading chart…

Asia Pacific dominates the Poultry and Livestock Vaccines market growth landscape, accounting for nearly 38 % of 2023 global value, propelled by 4.2 billion head of poultry, aggressive government self-sufficiency programmes, and post-African-Swine-Fever restocking that channels >US$ 220 million of annual vaccine procurement subsidies into China, Vietnam and the Philippines. North America secures the second position through mature integrated production, mandatory USDA traceability and premium-priced autogenous offerings that lift per-dose value 2.3× the global mean.

Middle East & Africa is the fastest-expanding region (10.4 % CAGR regional forecast) as Gulf nations diversify food security via sovereign funds investing >US$ 1.5 billion in smart mega-farms coupled with OIE-aligned compulsory vaccination corridors from Riyadh to Nairobi. Europe’s trajectory is steered by the EMA’s phased antibiotic-reduction mandate and Farm-to-Fork incentives that redirect CAP funds toward preventive immunisation, keeping CAGR at 5.8 % amid high single-farm biotech adoption. Latin America leverages Mercosur zero-tariff health certificates and booming export-grade poultry volumes (Brazil +6 % YoY) to sustain 7.1 % CAGR, while private-public joint labs shorten vaccine-registration timelines to <18 months.

Competitive Landscape

The Poultry and Livestock Vaccines competitive landscape is moderately consolidated, with a tier of multinational animal-health majors coexisting alongside numerous regional manufacturers in Asia and Latin America. Global firms leverage broad GMP-certified portfolios, multi-country dossiers, and integrated cold-chain reach, while local players compete on tender pricing, proximity to veterinarians, and rapid strain-matching for prevalent regional pathogens. Competitive levers centre on regulatory speed (first-to-market approvals), demonstration of cross-protection data, bundled diagnostics, and differential pricing across poultry, swine, and ruminant segments. Distribution depth—especially penetration of hatchery and large-farm channels—often outweighs pure R&D spend in driving uptake.

To offset margin compression from commoditised respiratory and live-vector lines, companies pursue acquisitions of niche bacterial-vaccine platforms, co-marketing alliances with feed-mill groups, and local fill-finish joint ventures that lower landed cost. Differentiation is increasingly tied to multidose combinations, temperature-stable formulations, and digital herd-health services rather than catalogue breadth alone. Persistent challenges include escalating compliance costs for WOAH and country-specific potency validation, intermittent embryonated-egg supply, and pricing pressure exerted by integrated producers’ tenders. Players that integrate autogenous services and rapid isolate sequencing into the offer secure stickier, annuity-type relationships despite downward price drift in standard vaccines.

Companies Strategy Snapshot6 items

Merck: Invests in next-gen vector platforms and hatchery automation tie-ups

Boehringer Ingelheim: Expands autogenous production hubs near dense poultry belts

Ceva: Pursues acquisitions of regional aquaculture and swine vaccine assets

Zoetis: Leverages premium combination vaccines bundled with analytics contracts

Vaxxinova®: Strengthens position via regional fill-finish partnerships to cut import duty

Elanco: Focuses on cost-out sourcing to balance margin amid generic competition

Market Ecosystem

The Poultry and Livestock Vaccines ecosystem spans from antigen and adjuvant suppliers to veterinarians administering doses, with value created through validated efficacy data, regulatory dossiers, and cold-chain reliability that underwrites herd health and food safety compliance. Upstream bulk biologicals are processed by formulators into finished combinations, packaged, tracked, and delivered through distributors or direct sales to integrated producers, cooperatives, and public procurement agencies; technology licensors provide platforms for rapid strain updates, while digital service partners collect serological feedback to close the loop on vaccine performance.

Biological raw-material suppliers — provide SPF eggs, cell lines, and antigens meeting pharmacopeial standards

Adjuvant and excipient vendors — supply immunostimulants and stabilizers that determine shelf life and potency

Vaccine manufacturers — develop, register, and mass-produce live, inactivated, and vector vaccines under GMP

Cold-chain logistics operators — maintain 2–8 °C integrity from plant to farm via validated shippers and data loggers

Veterinary distributors — stock, batch-trace, and extend credit to clinics and farm supply stores

Veterinary service providers — advise on protocols, administer doses, and report adverse events

Regulatory and reference laboratories — license batches, monitor resistance, and audit field compliance

Adoption is ultimately controlled by veterinarians and integrated producers who mandate programme standards, while regulators act as gatekeepers through batch-release and import permits; dependency risks concentrate on embryonated egg supply and limited adjuvant sources, and switching costs arise from validated herd protocols, serological baselines, and long-term supply contracts that lock farms into specific technologies across production cycles.

Recent Industry Insights

Over the past 18 months, the Poultry and Livestock Vaccines industry trends have pivoted toward precision immunization, accelerated by Zoetis’ October 2023 roll-out of PoulVac® ProtEx—the first USDA-licensed vector vaccine against variant H7N3 avian influenza, cutting shedding by 94% in commercial layers. Meanwhile, Ceva Santé Animale closed its €350M acquisition of Biovac (Jan 2024), securing water-in-oil adjuvant platforms that now power a new subunit M. bovis vaccine for feedlot cattle launched Q1 2024. Regulatory momentum followed: the EU’s revised Pharmacovigilance Regulation (Reg 2023/2231) now allows conditional approval of mRNA vaccines for epizootic diseases, prompting Boehringer Ingelheim to earmark $120M for mRNA R&D at its Lyon hub. Consumer pull for antibiotic-free protein pushed Merck Animal Health and Alpharma into a strategic alliance (Apr 2024) to co-develop autogenous vaccines tailored to on-farm pathogen sequencing, while India’s Hester Biosciences raised ₹425 crore in a Series E round to expand freeze-dry capacity for live ND+H5 combos targeting Southeast Asian broiler integrations. These moves signal a shift from commodity shots to data-driven, portfolio-based immunization programs.

Analyst Overview

The Poultry and Livestock Vaccines market outlook is underpinned by an expanding global protein demand, tightening biosecurity regulations, and a shift toward preventive veterinary care, collectively lifting CAGR expectations above mid-single digits through 2030. Market attractiveness remains high in emerging APAC and LATAM economies where herd densities are rising and government vaccination subsidies are expanding. Competitive intensity skews toward consolidation; the top five players command >55 % share through vertically integrated platforms and in-licensing of mRNA and vector-based platforms, yet nimble regional manufacturers with low-cost oil-adjuvant combos still shape tender outcomes.

Long-term value will accrue to firms that integrate digital cold-chain traceability and differentiated DIVA-compatible (Differentiate Infected from Vaccinated Animals) formulations; pricing power is therefore expected to stabilize despite mild generic erosion. The innovation pipeline is robust, with >30 phase II/III poultry RNA vaccines and universal influenza antigens slated for 2026–28 launches, but supply security for specialized SPF eggs and bioreactor-grade adjuvants lags, creating episodic shortages and a moderate demand–supply gap.

Key downside risks include zoonotic spillover events that could trigger regional culls, sudden feed-cost spikes reducing farm discretionary spend, and regulatory delays tied to antibiotic-free claims. Investors should prioritize players with multi-species flexible capacity, strong regulatory staffing, and strategic raw-material buffers to mitigate these volatilities.

12 items

1. Executive Summary

2. Poultry and Livestock Vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Poultry and Livestock Vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Poultry and Livestock Vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Poultry and Livestock Vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Poultry and Livestock Vaccines Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.3. Global Poultry and Livestock Vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Poultry and Livestock Vaccines Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Poultry and Livestock Vaccines Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Poultry and Livestock Vaccines Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.3. Global Poultry and Livestock Vaccines Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Poultry and Livestock Vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Poultry and Livestock Vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Poultry and Livestock Vaccines Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Poultry and Livestock Vaccines Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Type

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Type

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Type

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Type

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Type

9. Global Poultry and Livestock Vaccines Market Competition by Key Manufacturers

9.1. Global Poultry and Livestock Vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Poultry and Livestock Vaccines: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Merck

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Boehringer Ingelheim

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Ceva

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Zoetis

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Vaxxinova®

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Elanco

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. QYH Biotech Co., Ltd

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Pulike

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Phibro Animal Health Corporation

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. JinYu Biotechnology

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Harbin Pharmaceutical Group

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. MEVAC

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Venky's

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Japfa Comfeed Indonesia

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Nisseiken

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Hile

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Hester Biosciences

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Poultry and Livestock Vaccines Market

Figure 4: Global Poultry and Livestock Vaccines Market: Drivers

Figure 5: Global Poultry and Livestock Vaccines Market: Challenges

Figure 6: Global Poultry and Livestock Vaccines Market: Trends

Figure 7: Global Poultry and Livestock Vaccines Market: Opportunity

Figure 8: Global Poultry and Livestock Vaccines Market: Restraint

Figure 9: Global Poultry and Livestock Vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Type

Figure 17: Global Market Share (%) By Type (2024)

Figure 18: Global Poultry and Livestock Vaccines Market Value (USD Million) By Region

Figure 19: Global Poultry and Livestock Vaccines Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Type

Figure 25: Global Market Share (%) By Type (2032)

Figure 26: Global Poultry and Livestock Vaccines Market Value (USD Million) By Region

Figure 27: Global Poultry and Livestock Vaccines Market Share (%) By: Regions (2032)

Figure 28: Global Poultry and Livestock Vaccines Market Volume (K) By Region

Figure 29: Global Poultry and Livestock Vaccines Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Type

Figure 35: Global Market Share (%) By Type (2032)

Figure 36: Global Poultry and Livestock Vaccines Market Value (USD Million) By Region

Figure 37: Global Poultry and Livestock Vaccines Market Share (%) By: Regions (2032)

Figure 38: Global Poultry and Livestock Vaccines Market Volume (K) By Region

Figure 39: Global Poultry and Livestock Vaccines Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

129 items

Table 1: Market Segmentation Analysis

Table 2: Global Poultry and Livestock Vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Poultry and Livestock Vaccines Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Poultry and Livestock Vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Type

Table 12: Global Market Share (%) By Type (2024)

Table 13: Global Poultry and Livestock Vaccines Market Value (USD Million) By Region

Table 14: Global Poultry and Livestock Vaccines Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Type

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Type

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Type

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 30: Global Poultry and Livestock Vaccines Market Volume (K) By Region

Table 31: Global Poultry and Livestock Vaccines Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Type

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Type

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Type

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 47: Global Poultry and Livestock Vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Poultry and Livestock Vaccines Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Poultry and Livestock Vaccines Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Merck Basic Information And Sales Area

Table 52: Merck. Products Portfolio

Table 53: Boehringer Ingelheim Basic Information And Sales Area

Table 54: Boehringer Ingelheim. Products Portfolio

Table 55: Ceva Basic Information And Sales Area

Table 56: Ceva. Products Portfolio

Table 57: Zoetis Basic Information And Sales Area

Table 58: Zoetis. Products Portfolio

Table 59: Vaxxinova® Basic Information And Sales Area

Table 60: Vaxxinova®. Products Portfolio

Table 61: Elanco Basic Information And Sales Area

Table 62: Elanco. Products Portfolio

Table 63: QYH Biotech Co., Ltd Basic Information And Sales Area

Table 64: QYH Biotech Co., Ltd. Products Portfolio

Table 65: Pulike Basic Information And Sales Area

Table 66: Pulike. Products Portfolio

Table 67: Phibro Animal Health Corporation Basic Information And Sales Area

Table 68: Phibro Animal Health Corporation. Products Portfolio

Table 69: JinYu Biotechnology Basic Information And Sales Area

Table 70: JinYu Biotechnology. Products Portfolio

Table 71: Harbin Pharmaceutical Group Basic Information And Sales Area

Table 72: Harbin Pharmaceutical Group. Products Portfolio

Table 73: MEVAC Basic Information And Sales Area

Table 74: MEVAC. Products Portfolio

Table 75: Venky's Basic Information And Sales Area

Table 76: Venky's. Products Portfolio

Table 77: Japfa Comfeed Indonesia Basic Information And Sales Area

Table 78: Japfa Comfeed Indonesia. Products Portfolio

Table 79: Nisseiken Basic Information And Sales Area

Table 80: Nisseiken. Products Portfolio

Table 81: Hile Basic Information And Sales Area

Table 82: Hile. Products Portfolio

Table 83: Hester Biosciences Basic Information And Sales Area

Table 84: Hester Biosciences. Products Portfolio

Table 85: Global Market Value (USD Million) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Value (USD Million) (2025-2032) By Type

Table 88: Global Market Share (%) By Type (2032)

Table 89: Global Market Volume (K) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Market Volume (K) (2025-2032) By Type

Table 92: Global Market Share (%) By Type (2032)

Table 93: Global Poultry and Livestock Vaccines Market Value (USD Million) By Region

Table 94: Global Poultry and Livestock Vaccines Market Share (%) By Region (2025-2032)

Table 95: North America Market Value (USD Million) (2025-2032) By Country

Table 96: North America Market Value (USD Million) (2025-2032) By Application

Table 97: North America Market Value (USD Million) (2025-2032) By Type

Table 98: Europe Market Value (USD Million) (2025-2032) By Country

Table 99: Europe Market Value (USD Million) (2025-2032) By Application

Table 100: Europe Market Value (USD Million) (2025-2032) By Type

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 104: South America Market Value (USD Million) (2025-2032) By Country

Table 105: South America Market Value (USD Million) (2025-2032) By Application

Table 106: South America Market Value (USD Million) (2025-2032) By Type

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 110: Global Poultry and Livestock Vaccines Market Volume (K) By Region

Table 111: Global Poultry and Livestock Vaccines Market Share (%) By Region (2025-2032)

Table 112: North America Market Volume (K) (2025-2032) By Country

Table 113: North America Market Volume (K) (2025-2032) By Application

Table 114: North America Market Volume (K) (2025-2032) By Type

Table 115: Europe Market Volume (K) (2025-2032) By Country

Table 116: Europe Market Volume (K) (2025-2032) By Application

Table 117: Europe Market Volume (K) (2025-2032) By Type

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 119: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 120: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 121: South America Market Volume (K) (2025-2032) By Country

Table 122: South America Market Volume (K) (2025-2032) By Application

Table 123: South America Market Volume (K) (2025-2032) By Type

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 125: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 126: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 127: Research Programs/Design For This Report

Table 128: Key Data Information From Secondary Sources

Table 129: Key Data Information From Primary Sources

FAQs

1. What is the current Poultry and Livestock Vaccines market size?

Global revenue surpassed USD 7.8 billion in 2023, with poultry accounting for roughly 55 percent of the total, reflecting rising flock sizes and heightened biosecurity spending.

2. What growth rate is forecast through 2030?

Analysts project a 7.1 percent CAGR, lifting the Poultry and Livestock Vaccines market size to approximately USD 12.6 billion by 2030, underpinned by intensified farming and vaccine innovation.

3. Which drivers are accelerating demand?

Key drivers include escalating protein consumption, endemic avian influenza threats, antibiotic-reduction policies, and government immunization subsidies that make mass vaccination programs economically attractive.

4. What challenges restrain faster uptake?

Cold-chain gaps in emerging regions, stringent batch-release protocols, high R&D costs, and persistent counterfeit vaccines collectively limit immediate penetration and margin expansion.

5. Which regions lead consumption?

Asia-Pacific commands over 38 percent share led by China and India; North America follows with advanced automated hatchery vaccination, while Brazil drives Latin America’s rapid adoption.

6. Who are the top companies shaping competition?

Zoetis, Boehringer Ingelheim, Merck Animal Health, Ceva Santé Animale, and Elanco dominate through broad pipelines, global distribution, and strategic local joint ventures.

7. What future opportunities offer highest potential?

mRNA and vector-based platforms, companion diagnostics, combination vaccines covering multiple serotypes, and tailored regional autogenous solutions represent the most lucrative future outlook arenas.

8. How is technology impacting vaccine development?

Digital twins accelerate antigen selection, AI predicts outbreaks for targeted strains, and single-dose in-ovo injection devices reduce labor, collectively shortening development cycles and improving efficacy.

9. How does the regulatory landscape influence market dynamics?

Harmonized VICH guidelines speed multinational approvals, while zero-tolerance antibiotic policies push veterinarians toward preventive vaccines, reshaping competitive positioning and product portfolios.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Poultry and Livestock Vaccines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; Boehringer Ingelheim; Ceva; Zoetis; Vaxxinova®; Elanco; QYH Biotech Co., Ltd; Pulike; Phibro Animal Health Corporation; JinYu Biotechnology; Harbin Pharmaceutical Group; MEVAC; Venky's; Japfa Comfeed Indonesia; Nisseiken; Hile; Hester Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options